Penicillium Chrysogenum Var. Chrysogenum

Dosage for Penicillium Chrysogenum Var. Chrysogenum is highly individualized and must be determined by an allergist based on the patient's sensitivity level, as indicated by skin test results and clinical history.

Diagnostic Testing

• Skin Prick Test (SPT): Usually performed using a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, which is then pricked with a sterile lancet.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a 1:1000 to 1:100 w/v dilution may be injected (0.02 mL) into the dermis.

Immunotherapy (Allergy Shots)

Therapy is divided into two phases:

1. 1Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are given 1 to 2 times per week, with the dose increasing incrementally (e.g., 0.1, 0.2, 0.3, 0.5 mL) until the 'Maintenance Dose' is reached. This phase typically lasts 3 to 6 months.
2. 2Maintenance Phase: Once the maximum tolerated dose is reached (often 0.5 mL of a 1:10 or 1:20 w/v concentration), the interval between injections is increased to every 2 to 4 weeks. This phase usually continues for 3 to 5 years.

Penicillium Chrysogenum Var. Chrysogenum is generally considered safe for use in children, typically those aged 5 years and older. Dosing protocols for children are similar to adult protocols but may require smaller volume increments during the build-up phase if the child is highly sensitive. Immunotherapy is rarely started in children under the age of 5 due to the difficulty of communicating systemic symptoms and the risk of anaphylaxis in very small children.

Renal Impairment

No specific dosage adjustments are provided for renal impairment, as the systemic load of the protein extract is minimal. However, patients with severe renal disease may have altered fluid balance, which could theoretically complicate the management of anaphylaxis.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients (over 65). The primary concern is not the extract itself, but the patient's ability to tolerate the physiological stress of a systemic reaction or the medications (like epinephrine) used to treat such a reaction. Providers should evaluate cardiovascular health before beginning therapy.

• Administration: This medication must ONLY be administered by a healthcare professional. It is given as a subcutaneous injection (under the skin), usually in the back of the upper arm.
• Observation Period: Patients MUST remain in the doctor's office for at least 30 minutes following every injection to monitor for signs of a systemic allergic reaction (anaphylaxis).
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If the extract becomes cloudy or changes color, it should not be used.
• Site Rotation: Injections should be rotated between arms to minimize local tissue irritation.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has elapsed. If a maintenance dose is missed by more than a week, the allergist will typically reduce the dose for the next injection to ensure safety. Never attempt to 'double up' on doses at home.

An 'overdose' in the context of allergenic extracts usually refers to an injection given at a concentration higher than the patient's current tolerance level. This can lead to severe systemic reactions.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (0.3 mg IM for adults), oxygen, IV fluids, and potentially antihistamines or corticosteroids. Emergency medical services (911) should be summoned immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Penicillium Chrysogenum Var. Chrysogenum will experience some form of local reaction at the site of the injection. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch at the injection site that may appear within minutes or hours.
• Swelling (Edema): A raised area or 'knot' under the skin. If the swelling is larger than the size of a half-dollar (approx. 3 cm), it should be reported to the doctor before the next dose.
• Itching (Pruritus): Intense itching at the site, which can usually be managed with topical hydrocortisone or oral antihistamines.
• Tenderness: The arm may feel sore or heavy for 12-24 hours following the injection.

• Large Local Reactions: Swelling that extends from the shoulder to the elbow. While not life-threatening, this often necessitates a dose reduction.
• Fatigue: Some patients report feeling unusually tired for several hours after their immunotherapy session.
• Headache: Mild to moderate tension-type headaches.
• Nasal Congestion: A slight increase in 'hay fever' symptoms shortly after the injection.

• Vasovagal Syncope: Fainting or lightheadedness due to the needle stick or anxiety, rather than the extract itself.
• Persistent Lymphadenopathy: Swelling of the lymph nodes in the axilla (armpit) near the injection arm.
• Urticaria (Hives): Hives appearing on parts of the body other than the injection site.

> Warning: Stop taking Penicillium Chrysogenum Var. Chrysogenum and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, shortness of breath, or a persistent cough.
• Upper Airway Obstruction: A 'lump in the throat,' hoarseness, or difficulty swallowing.
• Cardiovascular Collapse: Rapid or weak pulse, dizziness, pallor, or a sudden drop in blood pressure.
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after an injection.
• Angioedema: Significant swelling of the face, lips, tongue, or around the eyes.

There are no known long-term 'toxic' effects of Penicillium Chrysogenum Var. Chrysogenum extracts. The primary long-term risk is the development of new sensitivities, though immunotherapy is generally thought to prevent the development of new allergies. Some patients may develop 'Arthus-type' reactions (Type III hypersensitivity), characterized by painful, firm swelling 6-12 hours after injection, caused by the formation of immune complexes.

WARNING: RISK OF ANAPHYLAXIS

Penicillium Chrysogenum Var. Chrysogenum and other allergenic extracts can cause severe, life-threatening systemic reactions, including anaphylaxis.

• Immunotherapy should only be administered in a clinical setting by personnel trained in the recognition and treatment of life-threatening allergic reactions.
• The facility must be equipped with emergency supplies, including epinephrine, oxygen, and airway management tools.
• Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
• Patients must be observed for at least 30 minutes after each injection.
• Patients should be informed of the risks and should be prescribed an epinephrine auto-injector for self-administration in case of a delayed reaction.

Report any unusual symptoms to your healthcare provider.

Penicillium Chrysogenum Var. Chrysogenum is a potent biological agent. Its safety depends entirely on correct administration, accurate dosing, and patient compliance. It is not a 'cure' for mold allergy but a disease-modifying therapy that requires a multi-year commitment.

As noted in the side effects section, the FDA requires a Black Box Warning for all allergenic extracts. This warning emphasizes that Penicillium Chrysogenum Var. Chrysogenum can cause anaphylaxis. Fatalities have occurred, typically in patients with poorly controlled asthma or those who received an incorrect dose. The warning also specifies that the drug should not be administered to patients who are taking beta-blockers, as these drugs can make anaphylaxis more difficult to treat.

• Asthma Control: Patients must have their asthma well-controlled (FEV1 > 80% of predicted) before receiving an injection. If a patient is experiencing an asthma flare-up on the day of their appointment, the injection MUST be postponed.
• Acute Illness: Injections should be withheld if the patient has a fever or a significant respiratory infection, as these can lower the threshold for a systemic reaction.
• Exercise Restriction: Patients should avoid vigorous exercise for 2 hours before and 2 hours after their injection. Exercise increases blood flow and can accelerate the systemic absorption of the allergen, increasing the risk of a reaction.
• Switching Vials: When moving from an old vial to a new vial (even of the same concentration), the dose is often reduced by 25-50% because the new vial may have higher potency due to less protein degradation.

• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before each injection to ensure lung function is stable.
• Symptom Review: The clinician will ask about any 'late' reactions from the previous dose before administering the next one.
• Skin Testing: Periodic re-testing (every 2-3 years) may be performed to assess the progress of desensitization.

Penicillium Chrysogenum Var. Chrysogenum does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until they are fully recovered and cleared by a physician.

Alcohol consumption should be avoided on the day of the injection. Alcohol can cause vasodilation, which may increase the rate of allergen absorption and potentially worsen an allergic reaction.

If a patient experiences repeated systemic reactions despite dose adjustments, the therapy may need to be discontinued. There is no 'withdrawal' syndrome associated with stopping allergenic extracts, but the patient's allergy symptoms will likely return to their baseline levels over several months.

> Important: Discuss all your medical conditions with your healthcare provider before starting Penicillium Chrysogenum Var. Chrysogenum.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These are contraindicated in patients receiving Penicillium Chrysogenum Var. Chrysogenum. Beta-blockers can increase the severity of anaphylaxis and, more importantly, they block the effects of epinephrine (adrenaline), which is the primary treatment for a life-threatening reaction. This combination can make a systemic reaction 'epinephrine-resistant.'

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These medications may increase the risk of systemic reactions or worsen the hypotension (low blood pressure) associated with anaphylaxis. Use with extreme caution.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of sympathomimetic drugs used to treat anaphylaxis, potentially leading to a hypertensive crisis if epinephrine is administered.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the pressor effects of epinephrine.

• Antihistamines (e.g., Loratadine, Cetirizine): These medications will suppress the 'wheal and flare' response during diagnostic skin testing. Patients must typically stop taking antihistamines for 3 to 7 days before skin testing to ensure accurate results. However, they are often continued during the immunotherapy phase to reduce local itching.
• Systemic Corticosteroids: Long-term use of high-dose steroids may mask the symptoms of an allergic reaction or slightly alter the immune response to the extract.

There are no direct food-drug interactions with Penicillium Chrysogenum Var. Chrysogenum. However, patients with 'Oral Allergy Syndrome' or known cross-reactivities should be cautious about trying new foods on the day of an injection, as this could complicate the diagnosis of a reaction.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat anaphylaxis.
• Feverfew/Ginkgo: These may have mild anti-platelet effects but are not known to interact directly with fungal extracts.

• Skin Tests: As mentioned, antihistamines, certain antidepressants (like mirtazapine), and H2 blockers (like famotidine) can cause false-negative results on skin prick tests.
• Total IgE: Immunotherapy may cause a transient rise in total serum IgE levels during the first few months of treatment, followed by a long-term decline.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the allergen or the rescue medication) rather than pharmacokinetic (affecting drug levels).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Penicillium Chrysogenum Var. Chrysogenum must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 persistently below 70% of predicted or those with recent hospitalizations for asthma are at an unacceptable risk of fatal bronchospasm during a reaction.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be able to tolerate the stress of anaphylaxis or the high doses of epinephrine required to treat it.
3. 3Hypersensitivity to Extract Components: If a patient has had a previous life-threatening reaction to a specific manufacturer's formulation that was not dose-related (e.g., an allergy to the phenol preservative).
4. 4Beta-Blocker Therapy: Due to the risk of epinephrine resistance.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system with allergens could exacerbate conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Patients with active cancer may have altered immune systems that make immunotherapy less effective or more unpredictable.
• Severe Atopic Dermatitis: May make skin testing results difficult to interpret.
• Young Children (<5 years): Due to communication barriers regarding systemic symptoms.

Patients allergic to Penicillium chrysogenum may show cross-sensitivity to other molds in the Aspergillus family or other Penicillium species. However, as previously noted, there is no consistent cross-sensitivity between Penicillium mold allergy and Penicillin antibiotic allergy. A patient can safely take penicillin antibiotics even if they have a positive skin test to the Penicillium fungal extract, provided they do not have a separate allergy to the drug itself.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Penicillium Chrysogenum Var. Chrysogenum.

FDA Pregnancy Category C.

• Risk Summary: There are no adequate and well-controlled studies of Penicillium Chrysogenum Var. Chrysogenum in pregnant women. The primary risk is not the extract itself (which is not teratogenic) but the risk of maternal anaphylaxis. A severe reaction can cause systemic hypotension, leading to placental hypoperfusion and fetal hypoxia (lack of oxygen to the baby), which can result in fetal distress or death.
• Clinical Practice: It is generally recommended not to start immunotherapy during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the allergist may choose to continue the therapy at the same or a slightly reduced dose throughout the pregnancy.

It is not known whether Penicillium allergens or the resulting antibodies are excreted in human milk. However, since these are large proteins and the systemic absorption is minimal, it is considered generally safe to continue Penicillium Chrysogenum Var. Chrysogenum immunotherapy while breastfeeding. No adverse effects have been documented in nursing infants.

• Safety: Safe for children 5 years and older. The efficacy in reducing the 'allergic march' (the progression from rhinitis to asthma) is well-supported in pediatric literature.
• Growth: There is no evidence that allergenic extracts affect growth or development.
• Considerations: Children should be monitored extra closely as they may describe the early signs of anaphylaxis as 'a funny feeling' or 'itchy throat' rather than specific medical symptoms.

Patients over 65 are at higher risk for complications from immunotherapy. This is largely due to the higher prevalence of underlying cardiovascular disease. If an elderly patient requires epinephrine for a reaction, it could trigger an arrhythmia or angina. Dose escalation should be done more conservatively in this population.

No specific studies have been conducted. Given the nature of the product, no dose adjustments are anticipated, but clinicians should be mindful of the patient's overall health and fluid status.

No adjustments are required. The liver is not the primary site of clearance for fungal allergenic proteins.

> Important: Special populations require individualized medical assessment.

Penicillium Chrysogenum Var. Chrysogenum acts as an immunomodulator. The molecular mechanism involves the presentation of fungal antigens (proteins like Pen c 1, Pen c 3) by Dendritic Cells to T-cells. In an allergic individual, this normally results in a Th2 response. Immunotherapy shifts this toward a T-regulatory (Treg) response. These Treg cells produce Interleukin-10 (IL-10), which signals B-cells to stop producing IgE and start producing IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody. When the patient is later exposed to environmental Penicillium mold, the IgG4 binds the mold proteins before they can reach the IgE on the mast cells, effectively preventing the allergic reaction at the source.

• Onset of Action: For skin testing, the effect is immediate (15-20 minutes). For immunotherapy, clinical improvement typically takes 3 to 6 months of consistent build-up.
• Duration of Effect: After a full 3-5 year course, the desensitization can last for many years, though some patients may eventually require 'booster' injections.
• Tolerance: The goal of therapy is the development of immunological tolerance, where the body no longer recognizes the fungal protein as a threat.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous depot) |

| Protein Binding | N/A (Interacts with IgE/IgG) |

| Half-life | Variable (Proteins degraded in hours; immune effect years) |

| Tmax | 30-60 minutes (for systemic absorption) |

| Metabolism | Tissue Proteases |

| Excretion | Renal (Metabolites) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides extracted from Penicillium chrysogenum mycelia.
• Solubility: Soluble in aqueous buffers; often stabilized with 50% glycerin.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various allergenic fractions.

Penicillium Chrysogenum Var. Chrysogenum belongs to the class of Allergenic Extracts, Fungal. It is grouped with other non-standardized extracts such as Alternaria alternata and Cladosporium herbarum. It is distinct from standardized extracts like Dermatophagoides farinae (dust mite) which have defined potency units.